SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Study to look at Covid-19 impact on blood cancer patients
Fri May 22nd - A new UK study is to be launched that will examine how patients who receive stem cell transplants for blood cancers and blood disorders react to severe Covid-19 infection. More
'Focus on blood clotting in Covid-19 patients'
Fri May 22nd - There is an urgent need to focus on medications that address dangerous blood clotting in Covid-19 patients, according to a leading haematologist. More
Immunotherapy hope for elimination of leukaemia stem cells
Fri May 22nd - Hematopoietic stem cells can be selectively eliminated using immunotherapy instead of chemotherapy, a new Swiss study has revealed. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

'Promising' COVID-19 vaccine revealed

Friday April 3rd, 2020

A potential vaccine for COVID-19 has been described for the first time after promising mice studies, US scientists have revealed today (2 April 2020).

Researchers at the University of Pittsburgh School of Medicine, USA, say the vaccine, delivered through a fingertip-sized patch, produces antibodies specific to SARS-CoV-2 at quantities that are believed to be sufficient for neutralising the virus.

It is hoped that human trials could begin in a few months’ time, following the promising results.

The study, outlined in the latest edition of EBioMedicine, is the first to be published after critique from fellow scientists at outside institutions that describes a candidate vaccine for COVID-19.

Co-senior author Dr Andrea Gambotto, associate professor of surgery at the Pitt School of Medicine, said their previous research into SARS-CoV in 2003 and MERS-CoV in 2014, which are closely related to SARS-CoV-2, demonstrated that a spike protein is important for inducing immunity against the virus.

Named PittCoVacc, short for Pittsburgh Coronavirus Vaccine, the vaccine uses lab-made pieces of viral protein to build immunity, similar to the way that flu vaccinations work.

A novel approach to deliver the drug – a painless microneedle array, which is a fingertip-sized patch with 400 tiny needles – was also used to increase potency.

Co-senior author Dr Louis Falo, professor and chair of dermatology at Pitt's School of Medicine and UPMC, said: “We developed this to build on the original scratch method used to deliver the smallpox vaccine to the skin, but as a high-tech version that is more efficient and reproducible patient to patient.”

The researchers say the system is highly scalable, with the protein pieces being manufactured by a “cell factory” that can be stacked further to multiply yield.

Purifying the protein also can be done at industrial scale by mass-producing the microneedle array using a centrifuge to spin the protein-sugar mixture into a mould.

The study shows that when PittCoVacc was tested in mice, it generated a surge of antibodies against SARS-CoV-2 within two weeks of application.

Although the mice have not been monitored long term, the research team says mice that received a MERS-CoV vaccine produced a sufficient level of antibodies to neutralise the virus for at least a year.

And so far, the antibody levels of the SARS-CoV-2 vaccinated animals seem to be following the same trend, they say.

Importantly, according to the research team, the SARS-CoV-2 microneedle vaccine maintains its potency even after being sterilised with gamma radiation, which is a crucial step towards making a product that is suitable for use in humans.

The researchers are applying for an investigational new drug approval from the U.S. Food and Drug Administration in the hope of starting a phase I human clinical trial in the next few months.

EBioMedicine 1 April 2020

http://dx.doi.org/10.1016/j.ebiom.2020.102743

Tags: Flu & Viruses | North America | Pharmaceuticals

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES